Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0378-6323.74999 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical expression of radiographic axial spondyloarthritis and its association with HLA-B27 in European and Ibero-American populations.
J Rheumatol
January 2025
Clementina López-Medina, MD, PhD, Department of Rheumatology, Reina Sofia University Hospital; GC-05 Group, Maimonides Institute for Biomedical Research of Cordoba, IMIBIC; Medical and Surgical Sciences, University of Cordoba, Cordoba, Spain.
Objective: To compare the clinical and sociodemographic characteristics of Ibero-American patients with radiographic axial spondyloarthritis (r-axSpA) to those of European patients, with a particular focus on the influence of HLA-B27.
Methods: This was an observational, cross-sectional, and multicentre study of patients who fulfilled the European Spondyloarthropathy Study Group (ESSG) criteria for SpA from the REGISPONSER and RESPONDIA registries. Univariate and multivariate analyses between European and Ibero-American populations stratified by HLA-B27 status were conducted.
[Not Available].
Tunis Med
January 2025
Department of Rheumatology, Kassab Institute of Orthopaedics, Mannouba. Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
Aim: To develop good practice recommendations (GPR) for the therapeutic management of patients with spondyloarthritis (SpA), including psoriatic arthritis.
Methods: Following standardised procedures, a systematic review of the literature was carried out on non-pharmacological and non-biological pharmacological treatments for SpA. The review was based on questions defined by a working group of 15 rheumatologists.
Axial spondyloarthritis.
Lancet
January 2025
Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany.
Axial spondyloarthritis manifests as a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. Although chronic back pain and spinal stiffness are typical initial symptoms, peripheral (ie, enthesitis, arthritis, and dactylitis) and extra-musculoskeletal (ie, uveitis, inflammatory bowel disease, and psoriasis) manifestations are also common. Timely and accurate diagnosis is challenging and relies on identifying a clinical pattern with a combination of clinical, laboratory (HLA-B27 positivity), and imaging findings (eg, structural damage on pelvic radiographs and bone marrow oedema on MRI of the sacroiliac joints).
View Article and Find Full Text PDFPrecision medicine using molecular-target drugs in psoriatic arthritis.
Ther Adv Musculoskelet Dis
January 2025
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan.
Article Synopsis
- Psoriatic arthritis (PsA) has a range of symptoms like skin lesions, joint pain, and increased risk of cardiovascular issues, highlighting its complexity and impact on lifestyle.
- Molecular-targeted therapies have been developed that focus on key inflammatory pathways and are now commonly used to manage PsA symptoms, though treatment options can be limited.
- The shift towards precision medicine, using patient stratification based on blood tests and cytokine levels, aims to enhance treatment efficacy, but more data and new trial designs are essential for its success.
Rheumatic Manifestations of Sarcoidosis.
Diagnostics (Basel)
December 2024
North Bristol NHS Foundation Trust, Bristol BS10 5NB, UK.
Sarcoidosis is a multisystem granulomatous inflammatory disorder, of unknown aetiology, which causes a wide spectrum of clinical phenotypes. It can present at any age, most commonly between 20 and 60 years, with a roughly equal sex distribution. Diagnosis is often delayed due to multiple diagnostic mimics, particularly joint disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!